1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

This business report from July 2014 is based on the identification, description and assessment of all relevant stakeholders in the field of botulinum neurotoxins. The report analyzes the existing product portfolios in regulated and less regulated markets, commercial information, and measures to maintain sales and market shares by upside indications and life cycle management measures. The report addresses the new wave of botulinum neurotoxin product candidates in development, such as biosimilars and biosuperior botulinum neurotoxins.

Special emphasis is put in the report on improvements by pharmaceutical technologies, such as liquid protein formulations and transdermal drug delivery technologies. The significance of recombinant DNA technology is discussed regarding botulinum neurotoxin engineering, modification and manufacturing. Chances and challenges for the stakeholders in the botulinum neurotoxin market are evaluated.

The market for botulinum neurotoxin products has significantly grown over the last years, due to new medical indications developed and due to more cosmetic procedures performed with botulinum neurotoxins in ageing societies in which physical appearance is highly valued. Although the botulinum neurotoxin market commercially is dominated by only one company, existing competitors, new players and technologies are setting the ground for biosuperiors as well as for biosimilars. As biosimilar botulinum toxins will put the price of first generation products under pressure, only innovation can justify higher prices.

Benefits from the report:

- Identify established and emerging players in the field;
- Find out which enabling technologies are attractive for the next generation;
- Understanding the driving forces for the future of the botulinum neurotoxin market;
- Learn the key success factors in marketing new botulinum neurotoxin products;
- Recognize the challenges acting on established stakeholders;
- Learn which technologies and product candidates are attractive for partnering;
- Find out which TCR therapeutic approaches are not yet tapped.

Table Of Contents

Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders
Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

Table of Contents

1.         Executive Summary

2.         Overview

2.1 Historical Background

2.2 Structure and Function of Botulinum Neurotoxins (BoNT)

3.         Botulinum Neurotoxin Products Available in Regulated Markets

3.1 Approved indications of BoNTs in regulated markets

3.2 Key product features of BoNT products in regulated markets

3.3 Pricing of botulinum toxin products in regulated markets

3.4 Botulinum toxin product sales and market shares

3.5 Commercial BoNT product success factors

3.6 Pipeline in a product

3.7 Product life cycle management of BoNT in EU/US

3.8 Discontinued development of BoNT in EU/US

4.         BoNTs in Less Regulated Markets

5.         Biosimilar Botulinum Neurotoxin

6.         Biosuperior, Next Generation Botulinum Neurotoxins

6.1 Ready-to-use injectable BoNT in liquid formulation

6.2 Transdermal delivery of BoNT in topical formulation

6.3 Engineered and modified botulinum toxins

7.         Botulinum Neurotoxin Market Stakeholders and Enabling Technologies

7.1 The established Western market players

7.2 Challenges for established BoNT market players

7.3 Enabling technologies for next generation BoNT

8.         Botulinum Neurotoxin Company Profiles

Allergan

Alphaeon

Anterios

CROMA Pharma

Daewoong Pharmaceutical Co

Eisai

Escape Therapeutics

Galderma

Hugel

Ipsen

Johnson andamp; Johnson (Mentor)

Lanzhou Institute of Biological Producs (LIBP)

Lipella Pharmaceuticals

Malvern Cosmeceutics

Medy-Tox

Merz Pharmaceuticals

OBI Pharma

Revance Therapeutics

Transdermal Corp

US WorldMeds

9.         References

10.       Competitor Analysis Tables

OnabotulinumtoxinA Pipeline

AbobotulinumtoxinA Pipeline

IncobotulinumtoxinA Pipeline

RimabotulinumtoxinB Pipeline

Novel and Biosimilar Botulinum Neurotoxin type A (BoNT/A) in Regulated Markets

Botulinum Neurotoxin type A (BoNT/A) in Less Regulated Markets

Liquid Formulation of Botulinum Neurotoxin type A (BoNT/A)

Topical Formulation of Botulinum Neurotoxin type A (BoNT/A)

Modified/Engineered Botulinum Neurotoxin

Corporate Botulinum Toxin Product Portfolios and Randamp;D Pipelines:

Allergan

Alphaeon

Anterios

CROMA Pharma

Daewoong Pharmaceutical Co

Eisai

Escape Therapeutics

Galderma

Hugel

Ipsen

Johnson andamp; Johnson (Mentor)

Lanzhou Institute of Biological Producs (LIBP)

Lipella Pharmaceuticals

Malvern Cosmeceutics

Medy-Tox

Merz Pharmaceuticals

OBI Pharma

Revance Therapeutics

Transdermal Corp

US WorldMeds

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.